Ranked by how strong the human evidence is — best supported first.
Best supportedBlood glucose responseNot enough evidence· no source yetThen, in order
A black sterile conk that grows on living birch trees in cold climates, harvested wild and sold as chunks, powder or extract. It is a fungal growth rather than a fruiting body, and cannot be commercially cultivated in the form that is sold.
Chaga is sold on antioxidant chemistry — it is genuinely rich in melanin, betulinic acid derived from its birch host, and polyphenols — and on essentially no human clinical evidence. There is no randomised trial of chaga for any condition. What there is instead is a specific and well-documented harm: chaga is exceptionally high in oxalate, and case reports describe oxalate nephropathy leading to irreversible kidney failure in people taking chaga powder daily, including a Japanese patient with liver cancer who progressed to end-stage renal disease. That is an unusual position for a supplement — no efficacy data at all, and a documented mechanism of serious organ damage.
Regulation: Sold as a dietary supplement in the US with no pre-market efficacy or safety review. Wild-harvested, with no species verification requirement and growing concern about sustainability of birch stands in some regions.
The amounts, forms and durations published trials of Chaga actually administered.
These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.
Studied for Common supplement use
1000–4000 mg
Powder or extract, daily
What products suggest. No human trial has established a dose for chaga, and the oxalate load rises directly with the amount taken, so higher intake is a documented risk rather than a stronger effect.
This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.
Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.
None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.
No timing research exists. Chaga is traditionally taken as a decoction at any time of day.
Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.
What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.
Glucose-lowering effects in diabetic mice are frequently cited in marketing. No human trial has tested this.
Not enough evidence. Not enough human research to say anything useful yet.
Immune effects have been described in mice and in cell culture. There are no controlled human trials of chaga for immune outcomes.
Not enough evidence. Not enough human research to say anything useful yet.
Chaga has a very high antioxidant capacity in test-tube assays. Those assays measure chemistry in a cuvette and have repeatedly failed to predict effects in people, and no human trial has measured oxidative stress markers after chaga.
Not enough evidence. Not enough human research to say anything useful yet.
Systematic review · Parasitology · 2020 · PMID 32052721
Systematic review · Current drug targets · 2023 · PMID 36503390
Deep research mode adds each paper’s own conclusion and stated limitations.
Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.
Worth knowing
Chaga is among the highest-oxalate materials sold as a supplement. Published cases describe people taking chaga powder daily for months who developed oxalate crystal deposition in the kidneys and progressed to dialysis-dependent renal failure. Anyone with kidney disease, a history of calcium oxalate stones, or dehydration risk should not take it, and nobody should take it daily at high doses.
Worth knowing
There is no randomised controlled trial of chaga for any outcome. Everything marketed about it comes from test-tube antioxidant assays, mouse studies and folk use. Given the documented kidney harm, that is an unfavourable balance.
Interaction
Interacts withWarfarin, antiplatelet drugs, insulin, sulfonylureas
Antiplatelet and glucose-lowering activity have been reported in laboratory work, making it a poor combination with anticoagulants or diabetes medication.
Avoid
Immune-stimulating activity in animal work makes it a questionable choice in autoimmune disease, and there is no safety data in pregnancy or breastfeeding.